About Us

Saugatuck Therapeutics is an early stage biotechnology company focused on the development of co- formulation of different types of immune based therapeutics in a novel delivery system (Nanolipogels-NLG) to improve safety and efficacy of different therapies.

Portage shareholders own approximately 70% of Saugatuck. Portage also serves as Chief Executive Officer, Chief Scientific Officer, and provides project management and financial support. In addition, Portage holds the Chairman and executive member seats on the Board of Directors.

Pipeline

COMPANY
ASSET
INDICATION
STAGE

Logo Saugatuck Ncomer

ASSET
PD1 + sm
PD1 + ap
INDICATION
Solid Tumor
Solid Tumor
STAGE
Preclinical
Preclinical

Programs

Saugatuck Therapeutics has an exclusive licensee of NLG technology for certain Immuno-oncology applications, which was invented by Dr. Tarek Fahmy at Yale University. NLG allows for different combination therapies to be encapsulated in a single nanomedicine, and delivered selectively to the tumor microenvironment. This novel approach, currently in preclinical testing, has the potential to minimize systemic side effects, as well as accommodate medicines with different physical and chemical properties for transport and release at the disease site.

Oncomer Limited will provide Saugatuck with a DNA aptamers for initial in vivo experiments in the NLG formulation for use in immuno-oncology applications. Early data confirm that this technology can load and release nucleotide therapeutics in vivo and has activity that is comparable or better than the corresponding antibody therapeutic.

Leadership

Dr. Walters has over 20 years of leadership and expertise in oncology/immunology …

Head CMC, Director

Mark Moody, PhD has more than twenty years of industry experience …

Non Exec Director

Linda retired from Bristol-Myers Squibb (BMS) as Vice President and …